For pharmaceutical companies involved in the synthesis of anticoagulants, particularly Dabigatran, the availability of high-quality intermediates is non-negotiable. Ethyl 3-[(3-Amino-4-methylaminobenzoyl)pyridin-2-ylamino]propionic Acid Ester, identified by its CAS number 212322-56-0, stands as a pivotal component in this complex manufacturing process. Its precise molecular structure and purity are critical factors that directly impact the efficacy and safety of the final drug product.

As a leading manufacturer and supplier based in China, we specialize in providing this essential pharmaceutical intermediate to the global market. Our commitment to quality is reflected in the stringent purity standards (typically 99%) that we maintain for CAS 212322-56-0. Procurement managers and research scientists alike depend on consistent quality and reliable availability to ensure uninterrupted production and successful drug development timelines. When you are looking to buy this intermediate, understanding the capabilities of your supplier is key.

We aim to be your preferred source for this vital chemical. Our robust manufacturing processes and dedication to quality control mean that you can trust the material you receive for your critical syntheses. We understand the competitive landscape of the pharmaceutical industry, which is why we focus on offering competitive pricing for bulk orders. Requesting a quote from us for Ethyl 3-[(3-Amino-4-methylaminobenzoyl)pyridin-2-ylamino]propionic Acid Ester will provide you with a clear understanding of the value we offer.

Beyond just supply, we pride ourselves on offering comprehensive support. Our technical team is available to assist with any inquiries regarding the properties, handling, or applications of this intermediate. Whether you are scaling up production or conducting early-stage research, having a reliable partner for your chemical sourcing needs is invaluable. For anyone seeking to purchase CAS 212322-56-0, consider us your trusted manufacturer and supplier, ready to support your pharmaceutical innovation.